Sugi Predict

Sugi Predict / Targets / PSMD1

PSMD1

26S proteasome non-ATPase regulatory subunit 1 · Q99460 · PSMD1 on Sugi Atlas →

5,961 patent compounds predicted against PSMD1, 4,568 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1478606 SCHEMBL1478606 0.58 12/20
SCHEMBL607010 SCHEMBL607010 0.56 12/20
SCHEMBL608381 SCHEMBL608381 0.53 12/20
SCHEMBL3170187 SCHEMBL3170187 0.51 12/20
SCHEMBL606616 SCHEMBL606616 0.51 12/20
SCHEMBL1477637 SCHEMBL1477637 0.57 11/20
SCHEMBL607972 SCHEMBL607972 0.55 11/20
SCHEMBL608782 SCHEMBL608782 0.54 11/20
SCHEMBL609278 SCHEMBL609278 0.54 11/20
SCHEMBL607553 SCHEMBL607553 0.54 11/20
SCHEMBL605822 SCHEMBL605822 0.54 11/20
SCHEMBL606932 SCHEMBL606932 0.53 11/20
SCHEMBL1477893 SCHEMBL1477893 0.53 11/20
SCHEMBL608362 SCHEMBL608362 0.53 11/20
SCHEMBL608599 SCHEMBL608599 0.53 11/20
SCHEMBL1327441 SCHEMBL1327441 0.53 11/20
SCHEMBL605129 SCHEMBL605129 0.52 11/20
SCHEMBL3170843 SCHEMBL3170843 0.52 11/20
SCHEMBL608009 SCHEMBL608009 0.52 11/20
SCHEMBL1478157 SCHEMBL1478157 0.52 11/20

Clinical trials — most relevant to PSMD1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease PHASE4UNKNOWN
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
Biologic Correlative Taxotere/AC PHASE2COMPLETED
A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis PHASE1/PHASE2COMPLETED
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors PHASE2COMPLETED
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy PHASE2NOT_YET_RECRUITING
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy PHASE2COMPLETED
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer PHASE2COMPLETED
Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma PHASE2COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM PHASE1WITHDRAWN
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma PHASE1COMPLETED
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer PHASE1COMPLETED
Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer PHASE1COMPLETED
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment nanUNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT) nanUNKNOWN
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS) nanUNKNOWN
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Collection of Blood Samples for DNA in Motor Neuron Disease nanCOMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit nanCOMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PSMD1 binder may also engage these)

ProteinNameSimilarity
Q5R5S4 — 1.000 Q5R5S4 →
Q5F418 — 1.000 Q5F418 →
Q3TXS7 — 1.000 Q3TXS7 →
O88761 — 0.997 O88761 →
P17427 — 0.976 P17427 →
P18484 — 0.975 P18484 →
AP2A2 AP-2 complex subunit alpha-2 0.966 landscape →
Q0VCK5 — 0.958 Q0VCK5 →
Q5R874 — 0.957 Q5R874 →
P97834 — 0.954 P97834 →
DHX9 ATP-dependent RNA helicase A 0.952 landscape →
XPO1 Exportin-1 0.952 landscape →
CDC16 Cell division cycle protein 16 homolog 0.951 landscape →
Q80U96 — 0.950 Q80U96 →
Q6NRT5 — 0.950 Q6NRT5 →
Q99LD4 — 0.950 Q99LD4 →
Q28141 — 0.948 Q28141 →
Q6P5F9 — 0.947 Q6P5F9 →
O88544 — 0.946 O88544 →
Q7SXR3 — 0.946 Q7SXR3 →
GPS1 COP9 signalosome complex subunit 1 0.946 landscape →
P53619 — 0.946 P53619 →
Q6GR10 — 0.946 Q6GR10 →
AP2A1 AP-2 complex subunit alpha-1 0.945 landscape →
Q8R349 — 0.945 Q8R349 →
RPTOR Regulatory-associated protein of mTOR 0.944 landscape →
Q66H80 — 0.944 Q66H80 →
Q3T178 — 0.944 Q3T178 →
Q9WUP7 — 0.943 Q9WUP7 →
Q5RA77 — 0.943 Q5RA77 →